GHRP-2 Stimulates Growth Hormone in GH-Deficient Little Mice
Background
Growth hormone (GH) deficiency is a condition characterized by insufficient production of growth hormone, leading to impaired growth and metabolic issues. In humans, this often requires lifelong GH replacement therapy. Growth hormone-releasing peptide-2 (GHRP-2) is a synthetic peptide known to stimulate GH release by acting on the ghrelin receptor. This study aimed to investigate if GHRP-2 could elicit a GH response in a specific genetic model of GH deficiency, the 'little mouse', which inherently lacks functional growth hormone-releasing hormone (GHRH) receptors.
Results
The study successfully demonstrated that GHRP-2 elicited a significant growth hormone (GH) response in the growth hormone-deficient little mice. Despite their genetic defect affecting the GHRH pathway, the pituitary somatotrophs in these mice retained sensitivity to GHRP-2, indicating an intact ghrelin receptor signaling pathway. This stimulation was observed consistently across the treated groups, confirming the peptide's ability to induce GH secretion even in the absence of a functional GHRH receptor. The most important finding was the clear and significant stimulation of growth hormone release by GHRP-2 in a model genetically predisposed to severe GH deficiency, highlighting an alternative pathway for GH secretion. Compared to vehicle-treated control mice, animals receiving GHRP-2 showed a marked elevation in circulating GH levels, suggesting a robust and pharmacologically relevant effect.
Why It Matters
This research is significant because it identifies an alternative pathway for stimulating growth hormone release in a severe model of GH deficiency. The finding that GHRP-2 can bypass the primary genetic defect in Ghrhr deficient mice suggests its potential as a therapeutic agent. This could lead to new treatment strategies for certain forms of human growth hormone deficiency where GHRH pathways are compromised or ineffective. Further research, including long-term efficacy and safety studies, would be necessary before considering human trials (e.g., Phase I or II clinical trials) for specific GH-deficient patient populations.